Replimune Plunges As FDA Issues Second CRL For RP1 In Advanced Melanoma

Replimune Group received a complete response letter from the FDA for its Biologics License Application for RP1 (vusolimogene oderparepvec), a major regulatory setback for the company’s lead biotech program. The CRL signals that the agency will not approve the application in its current form, creating material uncertainty around the product’s path to market. The news is likely to pressure REPL shares and could affect broader sentiment toward clinical-stage biotech approvals.

Analysis

Replimune Group received a complete response letter from the FDA for its Biologics License Application for RP1 (vusolimogene oderparepvec), a major regulatory setback for the company’s lead biotech program. The CRL signals that the agency will not approve the application in its current form, creating material uncertainty around the product’s path to market. The news is likely to pressure REPL shares and could affect broader sentiment toward clinical-stage biotech approvals.